<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01996384</url>
  </required_header>
  <id_info>
    <org_study_id>OHSU IRB 9664</org_study_id>
    <nct_id>NCT01996384</nct_id>
  </id_info>
  <brief_title>Provoked, Localized Vulvodynia Treatment With Acupuncture and Lidocaine Pilot Study</brief_title>
  <official_title>Acupuncture Augmentation of Lidocaine for the Treatment of Provoked, Localized vulvodynia-a Feasibility and Acceptability Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon College of Oriental Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Vulvodynia Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Council of Colleges of Acupuncture and Oriental Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon College of Oriental Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators research project is a randomized, controlled, single-blinded, feasibility
      pilot study. The investigators will study the feasibility of a novel treatment for women with
      Provoked Localized Vulvodynia (PLV) with acupuncture and 5% lidocaine cream. Lidocaine is a
      numbing agent and common first treatment for this disorder. Acupuncture is a treatment
      commonly used for other pain disorders. The investigators will compare two types of
      acupuncture (classical and non-classical) as a treatment for PLV, in addition to 5% lidocaine
      cream. Researchers want to determine if acupuncture is acceptable and convenient to women
      with PLV. The investigators hypothesize that classical acupuncture and 5% lidocaine cream
      will be better than non-classical acupuncture and 5% lidocaine cream to decrease PLV pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, controlled, single-blinded, pilot trial to study the feasibility and
      acceptability of acupuncture and 5% lidocaine. Patients will be recruited from the patient
      population of the Oregon Health &amp; Science University Vulvar Health Clinic. Thirty (30)
      patients with PLV will be enrolled as study participants into the study. Fifteen (15) will be
      allocated in the treatment (classical) acupuncture + 5% lidocaine group and fifteen (15) will
      be allocated in the control (non-classical) acupuncture + 5% lidocaine group via a computer
      generated randomization program to balance allocation based on four variables: pain
      intensity, smoking status, body mass index, and pain duration.

      The acupuncturist will interview each patient and perform an exam of the pulse and tongue. A
      standardized acupuncture treatment will be assigned, and both groups will receive 18
      acupuncture treatments that follow a standardized protocol on classical or non-classical
      acupuncture points, with or without mild electrical stimulation. All study participants will
      self-apply lidocaine cream to their genital region four times daily during the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tampon Test</measure>
    <time_frame>Weeks 1 and 12 study period</time_frame>
    <description>Primary outcome variable will be to measure the change in the reported pain of the &quot;Tampon Test&quot; (mean at Week 1) to the reported pain of &quot;Tampon Test&quot; (mean of Week 12);
Every week, study participants will be asked to fully insert and remove a tampon and rate the level of pain with insertion on a 10-point Visual Analog Scale (0 indicating no pain, 10 indication worst possible pain).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cotton Swab test</measure>
    <time_frame>Weeks -4, -3, -2, -1, 0, 1, 12 or 13 and 24.</time_frame>
    <description>Secondary outcome variable will compare the &quot;Cotton Swab Test&quot; with a blinded assessor reported pain at three timepoints. 1) change in reported pain at (mean at Weeks -2, -1, 0, and 1) to the reported pain (mean at Weeks 12 and 13; 2) change in reported pain (means Weeks -2, -1, 0, and 1) to the reported pain (mean at Week 24); 3) change in reported pain (mean at Week 12) to (mean at Week 24).
Vestibular tenderness will be assessed by light touch with a cotton swab by a blinded assessor to the study participant's: 1) vestibule (cotton swab test) at four defined points (1:00, 5:00, 7:00, and 11:00); 2) the perineum; 3) labia majora (2:00 and 8:00), and 4) labia minora (4:00 and 10:00). Tenderness at each location will be rated by the Study Participant on a 10-point scale (0 indicating no pain, 10 indicating worst possible pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcomes Measurement Information System (PROMIS) Scales</measure>
    <time_frame>At baseline visit, 6 weeks, 12 weeks, and 24 weeks</time_frame>
    <description>Assess changes in scores quality of life, vaginal discomfort, pain intensity, pain interference and behavior, anxiety, and depression at 6 weeks, 12 weeks, and 24 weeks compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction</measure>
    <time_frame>Weeks 12 and 24</time_frame>
    <description>Using 5-point scales (Very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied, Very dissatisfied), Study participants will be asked how satisfied they are with the study interventions and how satisfied they are with their pain relief.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expectation</measure>
    <time_frame>Week 1</time_frame>
    <description>Study participants will be asked about how much they 'expect' the study interventions will or will not help, how much they 'think' the intervention will or will not help, and how much they 'feel' about the intervention will or will not help via 10-point scales.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility</measure>
    <time_frame>Weeks 12 and 24</time_frame>
    <description>Assess feasibility by the number of study participants enrolled.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability</measure>
    <time_frame>Weeks 12 and 24</time_frame>
    <description>Assess acceptability by the number of study visits attended by participants enrolled.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tampon Test</measure>
    <time_frame>Weeks 1 and 6; Weeks 1 and 24</time_frame>
    <description>Secondary outcome variables will be to:
measure the change in reported pain of the &quot;Tampon Test&quot; (mean at Week 1) to the reported pain of &quot;Tampon Test&quot; (mean of Week 6);
measure the change in reported pain of the &quot;Tampon Test&quot; (mean at Week 1) to the reported pain of &quot;Tampon Test&quot; (mean of Week 24);
measure the change in reported pain of the &quot;Tampon Test&quot; (mean at Week 12) to the reported pain of &quot;Tampon Test&quot; (mean of Week 24).
Every week, study participants will be asked to fully insert and remove a tampon and rate the level of pain with insertion on a 10-point Visual Analog Scale (0 indicating no pain, 10 indication worst possible pain).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Traditional Chinese Medicine (TCM) Diagnosis Category</measure>
    <time_frame>Week 1</time_frame>
    <description>TCM Diagnosis Category will be recorded and tracked by the primary investigator to determine if it may be a potential predictor of treatment response.</description>
  </other_outcome>
  <other_outcome>
    <measure>24-hour mean pain score</measure>
    <time_frame>Baseline, Weeks 6, 12, and 24</time_frame>
    <description>In a daily pain diary, study participants will be asked to record the level of pain they are experiencing based via the 10-point VAS scale (0 indicates no pain, 10 indicates worst possible pain).</description>
  </other_outcome>
  <other_outcome>
    <measure>Frequency of intercourse</measure>
    <time_frame>Baseline, Weeks 6, 12, and 24</time_frame>
    <description>In a daily pain diary, study participants will be asked to record if they engaged in intercourse within the last 24 hours.</description>
  </other_outcome>
  <other_outcome>
    <measure>Intensity of Intercourse pain</measure>
    <time_frame>Baseline, Weeks 6, 12, and 24</time_frame>
    <description>In a daily pain diary, study participants will be asked to record the level of pain they are experienced with intercourse based via the 10-point VAS scale (0 indicates no pain, 10 indicates worst possible pain).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Provoked, Localized Vulvodynia</condition>
  <condition>Provoked Vestibulodynia</condition>
  <condition>Vulvar Vestibulitis</condition>
  <condition>Vulvodynia</condition>
  <arm_group>
    <arm_group_label>Classical Acupuncture + Lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study participants will attend 18 classical acupuncture sessions, twice a week for Weeks 1-6, and once a week for Weeks 7-12. A standardized acupuncture treatment will be assigned with classical acupuncture points and may or may not be stimulated with electroacupuncture. Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area based on up to three Traditional Chinese Medicine Diagnosis categories. Study participants will also be asked to gently apply 5% lidocaine cream four times daily (breakfast, lunch, dinner, and before bed).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-classical acupuncture + lidocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study participants will attend 18 non-classical acupuncture sessions, twice a week for Weeks 1-6, and once a week for Weeks 7-12. A standardized acupuncture treatment will be assigned with non-classical acupuncture points and may or may not be stimulated with electroacupuncture. Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area. Study participants will also be asked to gently apply 5% lidocaine cream four times daily (breakfast, lunch, dinner, and before bed).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Classical Acupuncture</intervention_name>
    <description>Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area. No needles will be inserted into the genital region. Locations needled will be in classical acupuncture points. On even-numbered visits, the needles may be electrically stimulated via an electro-acupuncture machine. Needles will be retained for 30 minutes per study visit. Acupuncture needles used are 0.18x30-40mm, manufactured by Dong Bae Corporation (DBC), Korea. The electrical acupuncture device is Pantheon Research Electrical Stimulator 8c, United States.</description>
    <arm_group_label>Classical Acupuncture + Lidocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Non-classical acupuncture</intervention_name>
    <description>Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area. No needles will be inserted into the genital region. Locations needled will be in non-classical acupuncture points. On even-numbered visits, the needles may be electrically stimulated via an electro-acupuncture machine. Needles will be retained for 30 minutes per study visit. Acupuncture needles used are DBC Brand, Korea, 0.18x30-40mm. The electrical acupuncture device is Pantheon Research Electrical Stimulator 8c, United States.</description>
    <arm_group_label>Non-classical acupuncture + lidocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>Study participants will gently apply 5% lidocaine cream four times daily to vulvar area.</description>
    <arm_group_label>Classical Acupuncture + Lidocaine</arm_group_label>
    <arm_group_label>Non-classical acupuncture + lidocaine</arm_group_label>
    <other_name>5% Lidocaine cream</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Literate, English speaking, premenopausal, women meeting Friedrich's criteria for
             Provoked, localized vulvodynia

          -  Reported introital dyspareunia longer than three months duration;

          -  Average pain score greater than 4 on Visual Analog Scale (VAS) at enrollment with
             cotton swab test and Tampon Test;

          -  Able to insert an Original Regular Tampaxâ„¢ tampon.

        Exclusion Criteria:

          -  Co-existing conditions leading to dyspareunia including generalized unprovoked
             vulvodynia, atrophic vaginitis, vulvovaginal dermatoses (e.g. lichen sclerosus), or
             genital infection (e.g. herpes simplex virus or yeast infection).

          -  Pregnant or postpartum and breastfeeding;

          -  Use of neuromodulator medications (e.g. Serotonin Norepinephrine Reuptake Inhibitors
             (SNRIs), Tricyclic Antidepressants, or anti-seizure medications) started in the last
             six months. If taken for longer, must be on a stable dose for at least six months and
             still report moderate to severe pain. Selective Serotonin Reuptake Inhibitors (SSRIs)
             are allowed;

          -  Postmenopausal as defined by surgical or natural menopause (no menses for 12 months);

          -  Chronic pelvic pain defined as daily, non-menstrual pain in pelvis or lower abdomen
             for longer than three months duration;

          -  Must be able to refrain from other treatments for PLV including non-traditional
             options (e.g. other medications, physical therapy, sex therapy, acupuncture,
             naturopathic remedies) during the course of the study (6 months).

          -  Use of SNRIs, lidocaine, or acupuncture within the last three months.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lee E Hullender Rubin, DAOM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon College of Oriental Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Women's Health Research Unit; Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://journals.lww.com/jlgtd/Citation/2017/10001/Abstracts.1.aspx</url>
  </link>
  <results_reference>
    <citation>Hullender Rubin LE, Mist SD, Schnyer RN, Leclair CM. Acupuncture Augmentation of Lidocaine Treatment for Provoked, Localized Vulvodynia. J Lower Genit Tract Dis. 2017; 21(4S):S2-S3.</citation>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2013</study_first_submitted>
  <study_first_submitted_qc>November 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2013</study_first_posted>
  <last_update_submitted>October 4, 2017</last_update_submitted>
  <last_update_submitted_qc>October 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon College of Oriental Medicine</investigator_affiliation>
    <investigator_full_name>Lee Hullender Rubin, DAOM, LAc</investigator_full_name>
    <investigator_title>Adjunct Research Faculty</investigator_title>
  </responsible_party>
  <keyword>Vulvodynia</keyword>
  <keyword>Provoked, localized vulvodynia</keyword>
  <keyword>vulvar vestibulitis</keyword>
  <keyword>provoked vestibulodynia</keyword>
  <keyword>vulvovaginal pain</keyword>
  <keyword>vulvar pain</keyword>
  <keyword>vaginal pain</keyword>
  <keyword>chronic pain</keyword>
  <keyword>lidocaine</keyword>
  <keyword>numbing agent</keyword>
  <keyword>anesthetic cream</keyword>
  <keyword>acupuncture</keyword>
  <keyword>electroacupuncture</keyword>
  <keyword>electrical stimulated acupuncture</keyword>
  <keyword>manual acupuncture</keyword>
  <keyword>classical acupuncture</keyword>
  <keyword>non-classical acupuncture</keyword>
  <keyword>Traditional Chinese Medicine</keyword>
  <keyword>TCM</keyword>
  <keyword>Chinese medicine</keyword>
  <keyword>Acupuncture and Oriental Medicine</keyword>
  <keyword>AOM</keyword>
  <keyword>treatment</keyword>
  <keyword>feasibility</keyword>
  <keyword>pilot study</keyword>
  <keyword>Patient Reported Outcomes Measure Information System</keyword>
  <keyword>Tampon Test</keyword>
  <keyword>cotton swab test</keyword>
  <keyword>pain diary</keyword>
  <keyword>Research Electronic Data Capture</keyword>
  <keyword>REDCap</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vulvodynia</mesh_term>
    <mesh_term>Vulvar Vestibulitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

